Page 141 - Haematologica August 2018
P. 141
Therapeutic effects of chidamide on myeloma-associated bone disease
Figure 7. Chidamide inhibited osteoclast differentiation and the function of chidamide in non-tumor-bearing mice was examined. (A) Serum CTX-I and PINP levels before (CTX-1, P>0.05, non-significant; PINP, ***P<0.001) and after intraperitoneal injections of sRANKL following chidamide treatment(CTX-1, *P<0.05; PINP, ***P<0.001). (B) TRAP staining of mouse femur bone tissues. (C) Chidamide treatment decreased the number of OCs (TRAP-positive cells, dark red staining) in the mouse femur compared with the vehicle group; ***P<0.001. (D) Micro-CT three-dimensional reconstructed images of the vehicle and chidamide groups. (E) Micro- CT parameters of the bone in the vehicle and chidamide groups. Trabecular numbers, ***P<0.001; trabecular space, **P<0.01; BV/TV, non-significant (ns). RANKL: Receptor activator of nuclear factor κ-Β ligand; CTX: carboxy-terminal telopeptide; PINP: amino-terminal propeptide.
A
B
CD
E
haematologica | 2018; 103(8)
1377
